Hua Medicine (Shanghai) logo

Hua Medicine (Shanghai)(SEHK) 2552

Market CapHK$2.09BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-75%
5 Year-52%
1 Year-44%
1 Month-13%
HK$2.09
-0.95%
-0.02Today
Hua Medicine (Shanghai) last closing stock price
MetricPriceDate
Last closeHKD 2.092026-10-14
Hua Medicine (Shanghai) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.44%HKD 2.362026-10-07
1 month-12.92%HKD 2.402026-09-14
3 month-27.68%HKD 2.892026-07-16
Year to date-32.14%HKD 3.082025-12-31
1 year-43.51%HKD 3.702025-10-14
3 year+30.62%HKD 1.602023-10-13
5 year-51.95%HKD 4.352021-10-15
Since inception-74.52%HKD 8.282018-09-14

Hua Medicine (Shanghai) Financials at a Glance

Market Cap

HK$2.09BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥1.02B

Net Income (TTM)

CN¥969.97M

EPS (TTM)

-HK$0.12

P/E Ratio

-17.46

Dividend

HK$0.00

Beta (Volatility)

0.09 (Low)

Price

HK$2.09

Volume

955,500

Open

HK$2.11

Previous Close

HK$2.11

Daily Range

HK$2.05 - HK$2.11

52-Week Range

HK$1.97 - HK$3.96

Estimated Earnings Date

Apr 1, 2027

2552 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hua Medicine (Shanghai)

Hua Medicine (Shanghai) Ltd. is a biopharmaceutical company focused on developing innovative therapeutic solutions for diabetes and other serious diseases. Established in 2011 and headquartered in Shanghai, the company is advancing its lead asset, Dorzagliatin, through various clinical trials to address unmet medical needs in the Chinese market.

Products and Services
  • Dorzagliatin, an oral medication for Type 2 Diabetes
  • Combination therapies with Metformin, Sitagliptin, and Empagliflozin
  • Exploration of treatments for NASH and Alzheimer's disease
Growth Outlook
  • Strong focus on diabetes treatment aligns with rising prevalence in China
  • Ongoing Phase I trials for multiple combination therapies enhance pipeline potential
  • Expansion into other therapeutic areas may diversify revenue streams
Financial Highlights
  • Recent quarterly revenue of 373.67 million CNY, showing growth from previous quarters
  • Cash and cash equivalents of 1.07 billion CNY, providing operational stability
  • Current ratio of 3.34 indicates strong liquidity position
Hua Medicine is positioned in the healthcare sector, specifically within drug manufacturing for specialty and generic medications. The company’s innovative approach to diabetes treatment, particularly through Dorzagliatin, addresses a significant health challenge in China, where diabetes rates are increasing. The ongoing clinical trials for combination therapies further enhance the company's potential to capture market share. Financially, the company has demonstrated resilience with a solid cash position, allowing for continued investment in research and development. The current ratio indicates a strong ability to meet short-term obligations, which is crucial for sustaining operations during the development phase of its products. The recent revenue growth reflects the company's ability to scale its operations effectively. Overall, Hua Medicine presents a compelling opportunity for investors interested in the biopharmaceutical sector, particularly in the rapidly growing diabetes treatment market. The combination of innovative product development and a strong financial foundation positions the company for future growth.
AI Generated • Oct 13, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

328

CEO

Li Chen, PhD

Website

www.huamedicine.com

Headquarters

Shanghai, SH 201203, CN

2552 Financials

Key Financial Metrics (TTM)

Gross Margin

60.64%

Operating Margin

-16.23%

Net Income Margin

-16.46%

Return on Equity

-10.61%

Return on Capital

-10.78%

Return on Assets

-7.00%

Earnings Yield

-5.73%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$2.09BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

998.64M

Volume

955.50K

Avg. Volume

1.58M

Financials (TTM)

Gross Profit

CN¥585.68M

Operating Income

-CN¥335.94M

EBITDA

-CN¥274.51M

Operating Cash Flow

-CN¥307.46M

Capital Expenditure

-CN¥10.88M

Free Cash Flow

-CN¥311.83M

Cash & ST Invst.

CN¥1.07B

Total Debt

CN¥354.20M

Hua Medicine (Shanghai) Performance Analysis

Hua Medicine (Shanghai) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 20,465,493N/A
20232023-12-31CNY 84,653,897313.6%
20242024-12-31CNY 277,444,208227.7%
20252025-12-31CNY 534,598,44392.7%
Hua Medicine (Shanghai) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3149.3%
Q22025-06-3041.9%
Q42025-12-3124.6%
Q22026-06-3037.9%
Hua Medicine (Shanghai) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.24-40.3%
20232023-12-31CNY -0.24-2.4%
20242024-12-31CNY -0.2815.7%
20252025-12-31CNY 1.19N/A
Hua Medicine (Shanghai) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3124.3%
Q22025-06-301192.9%
Q42025-12-31-106.0%
Q22026-06-3058.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥373.67M

+264.0%

Gross Profit

CN¥231.08M

+383.8%

Gross Margin

61.84%

N/A

Market Cap

HK$2.09BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$4.92M

N/A

Employees

424

N/A

Net Income

-CN¥29.78M

+79.1%

EBITDA

-CN¥14.04M

+92.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥1.07B

-19.9%

Total Debt

CN¥354.20M

+30.0%

Accounts Receivable

CN¥155.29M

+211.9%

Inventory

CN¥116.36M

+22.2%

Long Term Debt

CN¥119.14M

-33.9%

Short Term Debt

CN¥235.06M

+154.9%

Return on Assets

-7.00%

N/A

Return on Invested Capital

-9.41%

N/A

Free Cash Flow

-CN¥66.58M

+70.8%

Operating Cash Flow

-CN¥62.82M

+72.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$51.39-4.76%
NVDANvidia
$221.30-3.16%
CRWVCoreWeave
$65.78-15.46%
INTCIntel
$98.12-4.56%

Questions About 2552

What is the current price of Hua Medicine (Shanghai)?

Hua Medicine (Shanghai) is trading at HK$2.09 per share.

What is the 52-week range for Hua Medicine (Shanghai)?

Over the past 52 weeks, Hua Medicine (Shanghai) has traded between HK$1.97 and HK$3.96.

How much debt does Hua Medicine (Shanghai) have?

As of the most recent reporting period, Hua Medicine (Shanghai) reported total debt of CN¥336.01M.

How much cash does Hua Medicine (Shanghai) have on hand?

Hua Medicine (Shanghai) reported CN¥1.22B in cash and cash equivalents in its most recent financial results.

What is Hua Medicine (Shanghai)’s dividend yield?

Hua Medicine (Shanghai) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services